mirabegron
Selected indexed studies
- Mirabegron: Pediatric First Approval. (Paediatr Drugs, 2021) [PMID:34056686]
- Mirabegron: The most promising adipose tissue beiging agent. (Physiol Rep, 2021) [PMID:33650753]
- Efficacy and safety of vibegron compared with mirabegron for overactive bladder: A systematic review and network meta-analysis. (Low Urin Tract Symptoms, 2023) [PMID:36863312]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Efficacy and safety of vibegron compared with mirabegron for overactive bladder: A systematic review and network meta-analysis. (2023) pubmed
- Activation of β3-adrenergic receptor by mirabegron prevents aortic dissection/aneurysm by promoting lymphangiogenesis in perivascular adipose tissue. (2024) pubmed
- Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial. (2024) pubmed
- Mirabegron: Pediatric First Approval. (2021) pubmed
- Mirabegron: A Review in Overactive Bladder Syndrome. (2018) pubmed
- Mirabegron: The most promising adipose tissue beiging agent. (2021) pubmed
- Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis. (2023) pubmed
- Mirabegron for the Treatment of Ureteral Stent-related Symptoms: A Systematic Review and Meta-analysis. (2022) pubmed
- Mirabegron: a safety review. (2011) pubmed
- Mirabegron Versus Placebo and Other Therapeutic Modalities in the Treatment of Patients with Overactive Bladder Syndrome-A Systematic Review. (2025) pubmed